Primary iliocaval leiomyosarcomas: The path beyond surgery

Area of Science:

• Oncology
• Surgical Pathology
• Retroperitoneal Sarcoma Research

Background:

• Iliocaval leiomyosarcoma (ICLM) is a rare and aggressive retroperitoneal sarcoma.
• Current treatment lacks consensus on neoadjuvant/adjuvant chemoradiotherapy benefits.
• This study describes the natural history of chemotherapy-naïve ICLM.

Purpose of the Study:

• To describe the natural history of ICLM treated in a tertiary cancer center.
• To explore potential strategies for improving oncological outcomes in ICLM patients.

Main Methods:

• Prospective database analysis of 30 patients with primary non-metastatic ICLM.
• Surgical resection performed between 2003 and 2018.
• Median follow-up of 70.0 months.

Main Results:

• No 90-day mortality observed.
• 16.7% local recurrence, 36.7% distant metastasis.
• Median overall survival of 41.0 months; 5-year overall survival rate was 32.1%.
• Tumor grade and >600 mL blood loss identified as key prognostic factors.

Conclusions:

• ICLM management should be centralized in high-volume sarcoma centers.
• Integration of tumor biology and multi-center trials are crucial for improving outcomes.
• Further insights into neoadjuvant chemotherapy efficacy are anticipated.